The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Long-term PFS outcomes from PERSEUS & practical applications for treating NDMM
Pieter Sonneveld, MD, PhD, Erasmus MC, Rotterdam, Netherlands, discusses long-term outcomes from the PERSEUS trial (NCT03710603), which shows unprecedented progression-free survival (PFS) with daratumumab combined with bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed multiple myeloma (NDMM). Prof. Sonneveld notes that about 70% of patients who achieved measurable residual disease (MRD) negativity and a complete response could stop daratumumab and continue lenalidomide alone after a certain period, and that daratumumab plus lenalidomide maintenance improves response beyond induction and consolidation. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So these progressive free survival data are unprecedented in patients with newly diagnosed multiple myeloma. It’s longer than any other regimen that’s currently applied in routine clinical practice in the frontline. And consequently it has now been adopted by many countries and also in the control arm of many trials as the standard. It’s a new standard of care for newly diagnosed patients to be used as induction before autologous transplant is planned, to be used in consolidation...
So these progressive free survival data are unprecedented in patients with newly diagnosed multiple myeloma. It’s longer than any other regimen that’s currently applied in routine clinical practice in the frontline. And consequently it has now been adopted by many countries and also in the control arm of many trials as the standard. It’s a new standard of care for newly diagnosed patients to be used as induction before autologous transplant is planned, to be used in consolidation. So in the trial, patients who received dara VRd induction and consolidation continued with daratumumab lenalidomide maintenance. If they had two years of MRD negativity and one year of CR at least, two years of treatment, they could stop daratumumab and continue with lenalidomide alone. Approximately 70% of the patients achieved this, and they continued for some period of time, a median of two years, with daratumumab, and then they could stop daratumumab and continue with len alone. Those patients that were not MRD-negative before the start of maintenance, of those patients, approximately half, 55% converted from MRD-positive to MRD-negative during the maintenance, indicating that daratumumab plus lenalidomide in the maintenance is a very effective regimen, not only to maintain the response, but also to improve the response beyond what has been achieved in the induction and the consolidation phase. So currently dara-len is accepted and approved in many countries already, across Europe and also around the world. And I think it will remain the standard for some time to come.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
